Funded MSc + PhD Studentship: Delivery of live biotherapeutics for restoration of women’s reproductive health
Calla Lily Clinical Care is delighted to partner with the University of Warwick for this fully funded (incl student stipend) four-year iCASE studentship from September 2025, available as part of Warwick’s MRC-funded Doctoral Training Partnership (DTP). Vaginal microbiota play a key role in women’s reproductive health. Disruption of the normal vaginal microbiome is associated with inflammation …
Presenting at the Mid-Atlantic Capital Conference in Philadelphia
Today, I had the privilege of presenting Calla Lily Clinical Care’s latest innovation, Callavid®, at the MidAtlantic Capital Conference with PACT in Philadelphia. It’s an exciting step forward in women’s health, particularly for those navigating the challenges of IVF and miscarriage. Our Callavid technology harnesses the power of intravaginal drug delivery initially through our medical …
Precious Kilimo joins as MBA Strategy Intern
A warm welcome from myself, Lara, and the entire Calla Lily Clinical Care Team to Precious Kilimo, who joins us as an MBA Intern from London Business School where she is a Mo Ibrahim Foundation Scholar. 🏛 Prior to business school, Precious was instrumental in scaling Maisha Meds, a Kenyan health tech non-profit from a $300k …
A Look at Three Common Medications That Can Be Delivered Intravaginally
When one thinks about yeast infections, menopause and fertility support, the conversation usually revolves around pills or injections. But there’s a better, more targeted way to achieve results. The era of blanket treatments is fading. I used to joke that medicine isn’t Burger King–you can’t just have it your way. Except, that’s exactly what is …
Professor Andy Lewis presents at PODD 2024 in Boston
We had a great 2 days at the Partnerships in Drug Delivery PODD Conference in Boston with team members Professor Andrew Lewis and Dr Lara Zibners representing Calla Lily. Besides Andy’s well received presentation on our Callavid vaginal drug delivery platform, there were also superb connections made with the wider drug delivery technology community, and …
Why Intravaginal Drug Delivery Is the Future of Women’s Health
When we talk about advancements in healthcare, the vagina doesn’t often make it into the conversation. But it should. Hell, it’s standard dinner conversation at my house. The power of the vagina as a vessel for targeted, effective treatment is an emerging trend in women’s health. A trend geared toward smarter, safer, more effective medication …
Pitching at the Merck Innovation Challenge
What a privilege it was for Lara and I to present Calla Lily Clinical Care to senior members of Merck Group and M Ventures . Selected out of 100+ women’s health startups from around the world, we were able to share our vision for our transformational Callavid drug delivery platform, beginning with pregnancy & fertility. …
Pitching at the Merck Innovation Challenge
Many of you know my drive to co-found Calla Lily Clinical Care was driven by my personal journey as a infertility survivor. The memory that remains particularly vivid is the distress caused by the inadequate methods of administering progesterone— whether through injections, pessaries, tablets, or suppositories. Each option (including now rings) has its pros and …
Callavid to be featured at PODD Conference
Excited to announce that Calla Lily Clinical Care will be attending the PODD Conference in Boston next week! Our Principal Scientist Andrew Lewis and co-founder Lara Zibners will be showcasing our innovative vaginal drug delivery platform and its numerous applications beginning with pregnancy and fertility, and exploring new partnership opportunities. Stay tuned for updates on …
Returning to Stanford University / Stanford d.school
I’m thrilled to be heading back to Stanford University and The Stanford d.school for the first time since graduating! I’ll be in the Bay Area next week from October 21st, representing Calla Lily Clinical Care 🌸. I’m excited to reconnect with professors, industry leaders, and former collegues on our exciting Callavid and Phlovid progress. I’d …